-
European Psychiatry : the Journal of... Feb 2003
Topics: Adolescent; Antidepressive Agents, Second-Generation; Enuresis; Female; Humans; Obsessive-Compulsive Disorder; Paroxetine
PubMed: 12648899
DOI: 10.1016/s0924-9338(02)00010-x -
The Journal of Clinical Psychiatry Apr 2003
Topics: Anxiety Disorders; Depressive Disorder; Dose-Response Relationship, Drug; Female; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Somnambulism
PubMed: 12716257
DOI: 10.4088/jcp.v64n0420e -
International Journal of Environmental... Nov 2022Paroxetine is a common pharmaceutical to treat depression and has been found to pose threats to aquatic organisms. However, little is known about the effects of...
Paroxetine is a common pharmaceutical to treat depression and has been found to pose threats to aquatic organisms. However, little is known about the effects of paroxetine on the nutrient cycle in aquatic environments. Therefore, DNA metabarcoding is used in this study to analyze the effects of paroxetine on multi-trophic microorganisms and nitrogen transformation in river sediments. Although paroxetine has no significant effect on the diversity of microbenthos, changes in benthic nitrogen-converting bacteria are consistent with the change in the various forms of nitrogen in the sediment, indicating that paroxetine affects the nitrogen conversion process by affecting nitrogen-converting bacteria. In addition, it is found that paroxetine has the ability to influence nitrogen transformation in an indirect way by affecting the trophic transfer efficiency of higher trophic levels (meiofauna and protozoa, protozoa and protozoa), subsequently affecting the growth of nitrogen-converting bacteria through a top-down mechanism (i.e., predation).The results show that paroxetine affects nitrogen transformation directly by affecting nitrogen-converting bacteria and indirectly through top-down effects, emphasizing that the assessment of paroxetine's ecological risks should consider species within different trophic levels.
Topics: Food Chain; Rivers; Nitrogen; Paroxetine; Aquatic Organisms; Bacteria; Geologic Sediments; Ecosystem
PubMed: 36361481
DOI: 10.3390/ijerph192114602 -
Reproductive Toxicology (Elmsford, N.Y.) Apr 2023Paroxetine (PRX), a widely prescribed antidepressant, often leads to sexual dysfunction. The available management options such as sildenafil (SDF), are associated with...
Paroxetine (PRX), a widely prescribed antidepressant, often leads to sexual dysfunction. The available management options such as sildenafil (SDF), are associated with side effects. The present study investigates the fertility-boosting properties of isoliquiritigenin (ISL) on PRX-induced sexual dysfunction in male mice. We allocated fertile mice into six different groups (n = 5): group I- DMSO; group II- PRX; group III- co-administered PRX and SDF; group IV- ISL alone; group V- co-administered PRX and ISL (low dose); and, group VI- co-administered PRX and ISL (high dose). 14 days post treatment, animals were sacrificed, and the weights of the testis and epididymis were evaluated. Furthermore, sperm parameters, testicular and epididymal antioxidant levels, serum testosterone and nitric oxide (NO) levels, histoarchitecture of testis and epididymis, and markers of cellular toxicity were assessed. Results revealed that the PRX administration reduced organ weights, sperm count, intact acrosome, catalase (CAT), superoxide dismutase (SOD), glutathione (GSH), serum testosterone, and NO levels, and increased sperm abnormalities and MDA levels (a biomarker for lipid peroxidation). Additionally, we observed damage in the testis and epididymis. The toxicity biomarker study revealed a higher concentration of SGOT, SGPT, and ALP enzymes in the PRX-treated group. However, the co-administration of PRX with ISL ameliorated the adverse effect of PRX on the parameters mentioned above. The PRX+ISL (high) results were almost at par with the PRX+SDF group. The group that received ISL alone showed overall improvements. In conclusion, our comprehensive panel of tests indicates that ISL could be helpful in managing sexual dysfunction.
Topics: Male; Mice; Animals; Paroxetine; Semen; Testis; Antioxidants; Epididymis; Spermatozoa; Superoxide Dismutase; Glutathione; Testosterone; Biomarkers; Oxidative Stress; Sperm Count
PubMed: 36740106
DOI: 10.1016/j.reprotox.2023.108341 -
Journal of the American Heart... Sep 2022
Topics: Anterior Wall Myocardial Infarction; GTP-Binding Proteins; Humans; Myocardial Infarction; Paroxetine; Randomized Controlled Trials as Topic
PubMed: 36000427
DOI: 10.1161/JAHA.122.026362 -
Prescrire International Aug 2003
Topics: Humans; Paroxetine; Substance Withdrawal Syndrome
PubMed: 12908493
DOI: No ID Found -
International Journal of Molecular... Jun 2021Thus far, many hypotheses have been proposed explaining the cause of depression. Among the most popular of these are: monoamine, neurogenesis, neurobiology, inflammation...
Thus far, many hypotheses have been proposed explaining the cause of depression. Among the most popular of these are: monoamine, neurogenesis, neurobiology, inflammation and stress hypotheses. Many studies have proven that neurogenesis in the brains of adult mammals occurs throughout life. The generation of new neurons persists throughout adulthood in the mammalian brain due to the proliferation and differentiation of adult neural stem cells. For this reason, the search for drugs acting in this mechanism seems to be a priority for modern pharmacotherapy. Paroxetine is one of the most commonly used antidepressants. However, the exact mechanism of its action is not fully understood. The fact that the therapeutic effect after the administration of paroxetine occurs after a few weeks, even if the levels of monoamine are rapidly increased (within a few minutes), allows us to assume a neurogenic mechanism of action. Due to the confirmed dependence of depression on serotonin, norepinephrine, dopamine and γ-aminobutyric acid levels, studies have been undertaken into paroxetine interactions with these primary neurotransmitters using in silico and in vitro methods. We confirmed that paroxetine interacts most strongly with monoamine transporters and shows some interaction with γ-aminobutyric acid transporters. However, studies of the potency inhibitors and binding affinity values indicate that the neurogenic mechanism of paroxetine's action may be determined mainly by its interactions with serotonin transporters.
Topics: Animals; Binding Sites; CHO Cells; Cricetulus; GABA Plasma Membrane Transport Proteins; Humans; Molecular Docking Simulation; Neurotransmitter Agents; Paroxetine; Vesicular Monoamine Transport Proteins
PubMed: 34208199
DOI: 10.3390/ijms22126293 -
British Journal of Clinical Pharmacology Apr 2016The aim of this study was to perform an up-to-date meta-analysis on the risk of cardiac malformations associated with gestational exposure to paroxetine, taking into... (Meta-Analysis)
Meta-Analysis Review
AIMS
The aim of this study was to perform an up-to-date meta-analysis on the risk of cardiac malformations associated with gestational exposure to paroxetine, taking into account indication, study design and reference category.
METHOD
A systematic review of studies published between 1966 and November 2015 was conducted using embase and MEDLINE. Studies reporting major malformations with first trimester exposure to paroxetine were included. Potentially relevant articles were assessed and relevant data extracted to calculate risk estimates. Outcomes included any major malformations and major cardiac malformations. Pooled odds ratios and 95% confidence intervals were calculated using random-effects models.
RESULTS
Twenty-three studies were included. Compared with non-exposure to paroxetine, first trimester use of paroxetine was associated with an increased risk of any major congenital malformations combined (pooled OR 1.23, 95% CI 1.10, 1.38; n = 15 studies), major cardiac malformations (pooled OR 1.28, 95% CI 1.11, 1.47; n = 18 studies), specifically bulbus cordis anomalies and anomalies of cardiac septal closure (pooled OR 1.42, 95% CI 1.07, 1.89; n = 8 studies), atrial septal defects (pooled OR 2.38, 95% CI 1.14, 4.97; n = 4 studies) and right ventricular outflow track defect (pooled OR 2.29, 95% CI 1.06, 4.93; n = 4 studies). Although the estimates varied depending on the comparator group, study design and malformation detection period, a trend towards increased risk was observed.
CONCLUSIONS
Paroxetine use during the first trimester of pregnancy is associated with an increased risk of any major congenital malformations and cardiac malformations. The increase in risk is not dependent on the study method or population.
Topics: Abnormalities, Drug-Induced; Female; Heart Defects, Congenital; Humans; Maternal Exposure; Paroxetine; Pregnancy; Pregnancy Trimester, First; Risk Assessment; Selective Serotonin Reuptake Inhibitors
PubMed: 26613360
DOI: 10.1111/bcp.12849 -
Hospital Medicine (London, England :... Jan 2001Depression is reaching epidemic proportions in the western world. With each successive generation more people are becoming more severely depressed at a younger age. (Review)
Review
Depression is reaching epidemic proportions in the western world. With each successive generation more people are becoming more severely depressed at a younger age.
Topics: Adult; Antidepressive Agents, Second-Generation; Comorbidity; Depressive Disorder; Drug Interactions; Female; Humans; Intestinal Absorption; Male; Paroxetine; Randomized Controlled Trials as Topic; Treatment Outcome
PubMed: 11211460
DOI: 10.12968/hosp.2001.62.1.1503 -
Journal of the American Academy of... Feb 1999
Topics: Affect; Autistic Disorder; Child; Dose-Response Relationship, Drug; Humans; Impulsive Behavior; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sleep; Treatment Outcome
PubMed: 9951204
DOI: 10.1097/00004583-199902000-00004